On May 9, 2025, Liquidia Corp was sued by United Therapeutics for allegedly infringing a patent while seeking to commercialize its YUTREPIA inhalation powder, which is awaiting FDA approval. The lawsuit does not block FDA approval, which is expected by May 24, 2025.